Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma - Poll - MDSpire

Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma

  • By

  • Luisina María Solernó

  • Candela Llavona

  • Zahira Yasmine Saud

  • Mariana Carolina Onassis

  • María Florencia Gottardo

  • Martín Manuel Ledesma

  • Daniel Fernando Alonso

  • Juan Garona

  • July 1, 2026

  • 0 min

Share

Original Source(s)

Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma

  • by Luisina María Solernó, Candela Llavona, Zahira Yasmine Saud, Mariana Carolina Onassis, María Florencia Gottardo, Martín Manuel Ledesma, Daniel Fernando Alonso, Juan Garona

  • July 1, 2026

Related Content

Development and application of a prognostic model based on radiomics and artificial intelligence for patients with lung adenocarcinoma brain metastasis

This Week's CGT News: World's First Solid Tumor CAR T Approved in China 

  • June 30, 2026

  • 6 min
Case Report: Trazodone as a possible treatment for psychiatric adverse events related to ALK inhibitors